DoD Awards Morphotek $2.3M to Develop Biowarfare Therapies

Morphotek, Inc., a subsidiary of Japanese pharmaceutical company Eisai Co., received $2.3 million in funding from the Department of Defense to support the development of biologic- based monoclonal antibody therapies against biowarfare agents. Under the nine-month…

More Stories You Might Like